Published in Clin Rheumatol on February 25, 2012
Pathogenesis of Systemic Sclerosis. Front Immunol (2015) 0.89
Classification of morphea (localized scleroderma) Mayo Clin Proc (1995) 2.85
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Localized scleroderma. Curr Opin Rheumatol (2006) 1.99
Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol (1997) 1.95
Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol (2011) 1.89
Characterization of the alpha-chains of chick skin collagen and the nature of the NH2-terminal cross-link region. Biochemistry (1969) 1.63
Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis. J Lab Clin Med (1976) 1.57
Characterization of the cyanogen bromide peptides from the alpha-2 chain of chick skin collagen. Biochemistry (1969) 1.46
Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem (2001) 1.36
In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology (1993) 1.30
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum (2007) 1.23
Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther (2009) 1.22
The immunobiology of systemic sclerosis. Semin Arthritis Rheum (2008) 1.22
The alpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (I)-CB3 peptide of collagen. J Biol Chem (1990) 1.16
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis (2008) 1.13
Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol (1997) 1.09
Fibrosis in systemic sclerosis. Rheum Dis Clin North Am (2008) 1.08
Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol (2003) 1.04
Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol (2002) 1.01
Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol (1977) 0.96
Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol (1992) 0.95
Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis. Arthritis Rheum (1991) 0.91
Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy (1994) 0.91
Immune response to connective tissue components of the basement membrane. Connect Tissue Res (1982) 0.91
Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology (2003) 0.91
Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum (2000) 0.89
Expression of transforming growth factor-beta and platelet-derived growth factor in linear scleroderma. Biomedica (2003) 0.85
Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther (2006) 0.83
Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma. Folia Biol (Praha) (2007) 0.82
Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). Clin Exp Immunol (2010) 0.78
Differential regulations of matrix metalloproteinases and tissue inhibitors of metalloproteinases in dermal fibroblasts by dibutyril cyclic AMP. J Dermatol Sci (1997) 0.77
[Cellular immune phenomenon in scleroderma]. Dermatologica (1977) 0.77
Classification in systemic sclerosis. J Rheumatol (2006) 0.77
Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med (2002) 2.14
Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation (2005) 2.03
Infarct scar as living tissue. Basic Res Cardiol (2002) 1.43
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum (2009) 1.42
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol (2003) 1.28
Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum (2006) 1.23
20-hydroxyvitamin D₃ inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res (2012) 1.18
20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab (2013) 1.17
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res (2007) 1.16
Collagen-induced arthritis. Curr Protoc Immunol (2010) 1.13
Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol (2004) 1.13
Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res (2003) 1.10
Vitamin D analogs 17,20S(OH)2pD and 17,20R(OH)2pD are noncalcemic and exhibit antifibrotic activity. J Invest Dermatol (2011) 1.08
Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. J Rheumatol (2007) 1.02
Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse. Genomics (2009) 0.96
Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol (2003) 0.96
Chondrocyte response to cyclic hydrostatic pressure in alginate versus pellet culture. J Orthop Res (2006) 0.95
Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem J (2002) 0.95
Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model. J Immunol (2002) 0.94
Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res (2011) 0.93
Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol (2005) 0.92
Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets (2003) 0.92
Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther (2006) 0.91
The scar neovasculature after myocardial infarction in rats. Am J Physiol Heart Circ Physiol (2005) 0.89
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. Rheumatology (Oxford) (2010) 0.87
Stem cell repair of physeal cartilage. J Orthop Res (2004) 0.84
Congenic mice provide evidence for a genetic locus that modulates spontaneous arthritis caused by deficiency of IL-1RA. PLoS One (2013) 0.84
Genetic and molecular basis of quantitative trait loci of arthritis in rat: genes and polymorphisms. J Immunol (2008) 0.84
Snapshot of degenerative aging of porcine intervertebral disc: a model to unravel the molecular mechanisms. Exp Mol Med (2011) 0.84
T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol (2009) 0.83
Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther (2006) 0.83
T cell receptors recognizing type II collagen in HLA-DR-transgenic mice characterized by highly restricted V beta usage. Arthritis Rheum (2004) 0.83
Dual effects of IL-1 overactivity on the immune system in a mouse model of arthritis due to deficiency of IL-1 receptor antagonist. J Genet Genomics (2013) 0.83
Titanium particles and surface-bound LPS activate different pathways in IC-21 macrophages. J Biomed Mater Res B Appl Biomater (2006) 0.82
Matrix remodeling expression in anulus cells subjected to increased compressive load. Spine (Phila Pa 1976) (2005) 0.82
Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis. Thromb Res (2006) 0.82
Accumulation of LPS by polyethylene particles decreases bone attachment to implants. J Orthop Res (2006) 0.82
A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med (2010) 0.82
Administration of pamidronate alters bone-titanium attachment in the presence of endotoxin-coated polyethylene particles. J Biomed Mater Res B Appl Biomater (2007) 0.81
Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II. Arthritis Res Ther (2010) 0.81
A single-chain class II MHC-IgG3 fusion protein inhibits autoimmune arthritis by induction of antigen-specific hyporesponsiveness. J Immunol (2002) 0.81
Toward a broader understanding of aldosterone in congestive heart failure. J Renin Angiotensin Aldosterone Syst (2003) 0.81
Synergistic effect of combined growth factors in porcine intervertebral disc degeneration. Connect Tissue Res (2013) 0.81
Disseminated blastomycosis presenting as oligoarticular septic arthritis in a 12-year-old girl. Arthritis Rheum (2005) 0.80
Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol (2014) 0.80
Chemical Synthesis and Biological Activities of 20S,24S/R-Dihydroxyvitamin D3 Epimers and Their 1α-Hydroxyl Derivatives. J Med Chem (2015) 0.80
Analysis of candidate genes of spontaneous arthritis in mice deficient for interleukin-1 receptor antagonist. Genes Genet Syst (2012) 0.80
Aging affects response to cyclic tensile stretch: paradigm for intervertebral disc degeneration. Eur Cell Mater (2011) 0.79
Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. J Invest Dermatol (2006) 0.79
Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR/HLA-DR1) humanized model of arthritis. Arthritis Res Ther (2014) 0.79
Construction of a tissue-engineered annulus fibrosus. Artif Organs (2013) 0.78
Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta (2005) 0.77
Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford) (2009) 0.77
T cell immunity to type II collagen in the biobreeding rat: the identification and characterization of RT1u-restricted T cell epitopes on alpha 1(II). J Immunol (2004) 0.77
Genomic dissection and prioritizing of candidate genes of QTL for regulating spontaneous arthritis on chromosome 1 in mice deficient for interleukin-1 receptor antagonist. J Genet (2012) 0.77
Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis. Thromb Res (2008) 0.77
Macrophage response to high number of titanium particles is cytotoxic and COX-2 mediated and it is not affected by the particle's endotoxin content or the cleaning treatment. J Biomed Mater Res A (2011) 0.76
Molecular basis for T cell response induced by altered peptide ligand of type II collagen. J Biol Chem (2012) 0.76
Skin under the sun: when melanin pigment meets vitamin D. Endocrinology (2015) 0.76
A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta (2007) 0.76
Characterization of inhibitory T cells induced by an analog of type II collagen in an HLA-DR1 humanized mouse model of autoimmune arthritis. Arthritis Res Ther (2012) 0.76
Pathogenesis of collagen-induced arthritis: modulation of disease by arthritogenic T-cell epitope location. Immunology (2004) 0.75
Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum (2004) 0.75
Molecular characterization of an arthritogenic collagen peptide interacting with I-Ar. Immunology (2006) 0.75
Future nanomedicine for the diagnosis and treatment of osteoarthritis. Nanomedicine (Lond) (2014) 0.75
Retinal Vasculitis and Choroidopathy in Pediatric-Onset Mixed Connective Tissue Disease. J Clin Rheumatol (2017) 0.75
A 9-year-old boy with chronic urticaria and progressive spondyloarthritis. Allergy Asthma Proc (2013) 0.75
Fever and rash. Clin Pediatr (Phila) (2008) 0.75
1alpha,25-Dihydroxyvitamin D3 enhances proliferation of rat prostate cancer cells in the presence of living bone. J Steroid Biochem Mol Biol (2007) 0.75
A fatal presentation of dermatomyositis with facial swelling. Int J Pediatr Otorhinolaryngol (2012) 0.75
The complexity in hunting for candidate genes within QTL that determine susceptibility to arthritis in rats. Crit Rev Immunol (2008) 0.75
Titanium particles that have undergone phagocytosis by macrophages lose the ability to activate other macrophages. J Biomed Mater Res B Appl Biomater (2008) 0.75
Chondrocyte injection in distraction epiphysiolysis (rabbit model). J Orthop Res (2006) 0.75
Bone mineral density and turnover in non-corticosteroid treated African American children with juvenile rheumatoid arthritis. J Rheumatol (2006) 0.75